diaDexus, Inc. today announced the release of a supplement to The American Journal of Cardiology, Vol. 101, No 12A June 16, 2008 that includes an expert consensus panel recommendation to include ...
San Francisco, CA - The FDA has granted market clearance to a lipoprotein-associated phospholipase A2 (Lp-PLA2) test for coronary heart disease (diaDexus Inc). "Receiving marketing clearance for the ...
The AACE is the third major association of medical professionals to underscore the value of Lp-PLA2. The new recommendations complement medical guidelines published by the American College of ...
diaDexus, Inc, a company developing and commercialising proprietary cardiovascular diagnostic products, has received 510(k) clearance from the US Food and Drug Administration (US FDA) for its PLAC ...
Houston, TX - The novel inflammatory marker lipoprotein-associated phospholipase A 2 (Lp-PLA 2) and high-sensitivity C-reactive protein (hs-CRP) were higher in middle-aged men and women who ...
Coronary heart disease (CHD) kills more than 385,000 people in the United States each year, and more than half of those who die suddenly have no previous symptoms. A new blood test that could reduce ...
New Orleans, LA, November 9, 2004 – High levels of an enzyme – lipoprotein-associated phospholipase A2 (Lp-PLA2) – believed to trigger a cascade of inflammatory events in atherosclerosis can ...
A new test makes it easier for doctors to measure a fairly new indicator of heart disease risk — one that is especially helpful for African-American women. The U.S. Food and Drug Administration ...
diaDexus, Inc. and the Methodist DeBakey Heart Center today announced the publication of a landmark study in the American Medical Association's Archives of Internal Medicine demonstrating a greater ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results